Loading
Ocugen, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Dec 2024.
Ocugen, Inc.: what insiders have been doing
Ocugen, Inc. is a Healthcare & Pharma company based in Malvern. Its directors and officers file their transactions with SEC (Form 4). 4 insiders have disclosed 11 filings since 18 October 2025.
No insider bought on the market over the period, while 1 insider filed 4 sales totalling €951k. Musunuri Shankar filed the largest sale, €451k, on 11 September 2026, which represents 0.15% of the company's market value.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 11 filings, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 3 purchases and 17 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 4.4 m USD and net income at -67.8 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
80
Thresholds
n/a
Buy Volume
€122,755
3 ops. · all time
Sell Volume
€10M
17 ops. · all time
Who traded when
BuySaleShankar Musunuri4 sales
Kirsten Castillo1 buy
Prabhavathi Fernandes1 buy
Since the insiders bought
- +33.7%Entry US$0.90 · Close at T+365 US$1.21
- +27.8%Entry US$0.97 · Close at T+365 US$1.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ocugen, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$12.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.89
Analyst consensus
6 analystsStrong buy
US$8.00Target US$12.17(+1274%)US$22.00
Income statement
RevenueUS$4.4M
EBITDA-US$60.3M-1366% margin
Net income-US$67.8M-1537.4% margin
Valuation
PER (forward)-3.5x
P/Book72.9x
Beta2.27
Balance sheet & cash
Market capUS$300.2M
Total debtUS$33.1M
Free Cash Flow-US$57.1M
Debt / Equity574%
Profitability & ownership
ROE-660.0%
ROA-48.4%
% insiders1.5%
% institutions43.4%
Last declaration on 13 October 2026
Declarations80 total
468,727 shares@ US$0.950.14% mcap12.8% of flowCommon StockSEC:0001628280-26-065797:0
57,264 shares@ US$0.950.017% mcap1.6% of flowCommon StockSEC:0001628280-26-065797:1
525,991 shares@ US$0.94670.15% mcap46.7% of flowCommonSEC144:0001628280-26-065563
468,727 shares@ US$1.120.15% mcap17.0% of flowCommon StockSEC:0001628280-26-061626:0
57,264 shares@ US$1.120.019% mcap2.1% of flowCommon StockSEC:0001628280-26-061626:1
525,991 shares@ US$1.12120.17% mcap100.0% of flowCommonSEC144:0001628280-26-061150
15,000 shares@ US$0.510.1% of flowCommon StockSEC:0001104659-26-039361:0
112,205 shares@ US$0.460.9% of flowCommon StockSEC:0001104659-26-039361:1
66,929 shares@ US$1.421.7% of flowCommon StockSEC:0001104659-26-039361:2
3,123,201 shares0Common StockSEC:0001470831-26-000020:0
207,300 shares0Common StockSEC:0001470831-26-000019:0
177,146 shares@ US$0.89455.8% of flowCommon StockSEC:0001062993-25-000405:0
41,633 shares@ US$0.894550.2% of flowCommon StockSEC:0001062993-25-000406:0
10,000 shares@ US$0.909566.1% of flowCommon StockSEC:0001104659-24-124587:0
Canonical exit: 24 Feb 2025 (T+90)
25,000 shares@ US$0.91397.1% of flowCommon StockSEC:0001062993-24-019706:0
Canonical exit: 20 Feb 2025 (T+90)
842 shares@ US$1.171.2% of flowCommon StockSEC:0001062993-24-017006:0
917 shares@ US$1.421.7% of flowCommon StockSEC:0001062993-24-013292:0
41,633 shares@ US$0.65334.4% of flowCommon StockSEC:0001062993-24-000558:0
180,204 shares@ US$0.6534.1% of flowCommon StockSEC:0001062993-24-000559:0
842 shares@ US$0.410.4% of flowCommon StockSEC:0001062993-23-018252:0
917 shares@ US$0.510.6% of flowCommon StockSEC:0001062993-23-013810:0
200,278 shares@ US$0.49931.9% of flowCommon StockSEC:0001062993-23-013749:0
Canonical exit: 12 Sept 2023 (T+90)
37,877 shares@ US$1.251.7% of flowCommon StockSEC:0001062993-23-004080:0
7,102 shares@ US$1.2511.5% of flowCommon StockSEC:0001062993-23-004084:0
1,913 shares@ US$1.25100.0% of flowCommon StockSEC:0001062993-23-004082:0
25 of 80 declarations
About Ocugen, Inc.
Ocugen, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ exchange in the United States. Headquartered in Malvern, Pennsylvania, the company was co-founded in 2013 and has built its profile around gene and cell therapy programs, with a strong emphasis on ophthalmology and rare retinal diseases. Unlike a diversified large-cap pharma company, Ocugen is a development-stage biotech whose valuation is driven primarily by clinical progress, regulatory milestones, and partnering opportunities rather than by established commercial sales.
The company’s core franchise is centered on a pipeline of genetic medicines designed to address serious, underserved eye disorders. Its lead program, OCU400, is being advanced as a gene therapy candidate for retinitis pigmentosa, an inherited retinal disease that can lead to progressive vision loss. Ocugen is also developing OCU410ST for Leber congenital amaurosis and related retinal disorders, along with additional ocular programs such as OCU200. In practical terms, the business model is typical of a platform biotech: create differentiated assets, advance them through clinical development, and seek value creation through regulatory approvals, partnerships, and eventual commercialization or licensing.
Read moreShow less
From a competitive standpoint, Ocugen operates in a crowded and capital-intensive field dominated by larger biotech peers, specialty ophthalmology companies, and gene-therapy developers with deeper balance sheets. Its strategic advantage lies in its focus on rare eye diseases, where unmet medical need remains high and even modest clinical differentiation can have outsized strategic value. The company also uses licensing and collaboration agreements to expand reach and reduce development risk, particularly in international markets.
Recent developments indicate that Ocugen remains in a pre-revenue or early-revenue build-out phase, but with continued momentum across its pipeline. In 2026, the company released quarterly financial updates, discussed capital-raising activity, and highlighted that its cash position had been extended by financing and warrant exercises. Management has also been active in investor presentations and industry events, underscoring the importance of near-term catalysts. For investors, Ocugen should be viewed as a speculative ophthalmic biotech with meaningful upside tied to clinical execution, but also substantial binary risk typical of emerging gene-therapy developers.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
